Prodrug-based nanoparticulate drug delivery strategies for cancer therapy

Trends Pharmacol Sci. 2014 Nov;35(11):556-66. doi: 10.1016/j.tips.2014.09.008. Epub 2014 Oct 16.

Abstract

Despite the rapid developments in nanotechnology and biomaterials, the efficient delivery of chemotherapeutic agents is still challenging. Prodrug-based nanoassemblies have many advantages as a potent platform for anticancer drug delivery, such as improved drug availability, high drug loading efficiency, resistance to recrystallization upon encapsulation, and spatially and temporally controllable drug release. In this review, we discuss prodrug-based nanocarriers for cancer therapy, including nanosystems based on polymer-drug conjugates, self-assembling small molecular weight prodrugs and prodrug-encapsulated nanoparticles (NPs). In addition, we discuss new trends in the field of prodrug-based nanoassemblies that enhance the delivery efficiency of anticancer drugs, with special emphasis on smart stimuli-triggered drug release, hybrid nanoassemblies, and combination drug therapy.

Keywords: cancer therapy; combination therapy; hybrid nanoassemblies; prodrug nanoassemblies; stimuli-responsive.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Antineoplastic Agents / administration & dosage*
  • Antineoplastic Agents / chemistry
  • Drug Carriers / administration & dosage*
  • Drug Carriers / chemistry
  • Drug Delivery Systems / methods*
  • Humans
  • Nanoparticles / administration & dosage*
  • Nanoparticles / chemistry
  • Neoplasms / drug therapy
  • Prodrugs / administration & dosage*
  • Prodrugs / chemistry

Substances

  • Antineoplastic Agents
  • Drug Carriers
  • Prodrugs